News for Curis, Inc. (CRIS)

Recent Transaction Overview On December 31, 2024, Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, executed a significant stock transac

California-based clinical-stage biopharmaceutical company Revelation Biosciences, Inc. (REVB) is up over 125 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Curis Inc (CRIS) experienced a significant stock movement with a 6.19% increase in price, reaching $3.26 per share. The trading volume was 39,453 shares, with a

Curis stock plunges to 52-week low, hits $3.5 amid downturn

Curis Inc (CRIS), a biotechnology company, experienced a significant stock price increase of 5.46%. The stock is currently trading at $4.25 per share with a tra

Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ETCompany ParticipantsDiantha Duvall - Chief Financial OfficerJim...

Curis (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) is scheduled to announce Q3 earnings results on Thursday, November 14th, before market open.

Curis Inc. (CRIS) experienced a notable stock price increase of 5.08%, reaching $4.55 per share with a trading volume of 39,110 shares and a turnover rate of 0.

Curis (CRIS) to raise $12.1M through private placement, offering shares and warrants to investors at $5.045 per unit.

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc.  , a clinical-stage biopharmaceutical company focused on...

The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...

The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the...

The Tekla Healthcare Opportunities Fund's distribution yield appears the most sustainable. Click here to read my most recent analysis of THQ CEF here.

/PRNewswire/ -- DelveInsight's Esophageal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, esophageal...

- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection...

Revenue increased 14% annually driven by greater adoption of medical treatments. BRENTWOOD, Tenn., March 31, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings,...

/PRNewswire/ -- The HDAC (histone deacetylase) Inhibitors Market by Route of Administration, Distribution Channel, and Geography - Forecast and Analysis...

January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary... | January 5, 2023